CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(03): 377-379
DOI: 10.4103/ijmpo.ijmpo_8_17
Case Report

Human Leukocyte Antigen‑B27: The Genetic Predisposition Leading to Reactive Arthritis during Induction Phase Chemotherapy for Acute Myeloid Leukemia

Sandip P Bartakke
Department of Pediatrics, Bharati Vidyapeeth Medical College and Hospital, Pune, Maharashtra, India
,
Abhilasha Ashok Sampagar
Department of Pediatrics, Bharati Vidyapeeth Medical College and Hospital, Pune, Maharashtra, India
,
Vibha Sanjay Bafna
Department of Pediatrics, Bharati Vidyapeeth Medical College and Hospital, Pune, Maharashtra, India
,
Putun Patel
Department of Pediatrics, Bharati Vidyapeeth Medical College and Hospital, Pune, Maharashtra, India
› Author Affiliations
Financial support and sponsorship Nil.

Abstract

We report a case of reactive arthritis (ReA) during induction phase chemotherapy of a 15-year-old male patient with acute myeloid leukemia (AML) M4 with inv(16), most probably due to a genetic predisposition of being human leukocyte antigen b27 (HLA-B27) positive. The episode of ReA recurred during consolidation therapy; however, the patient was asymptomatic after the completion of treatment. The link between HLA-B27 and a large family of inflammatory rheumatic diseases is a well-established fact, but interestingly, there is also a molecular link between HLA-B27 and hematological malignancies. This case brings to our notice, the common immunological, molecular, and microbiological link between AML, HLA-B27, and ReA. It also emphasizes the fact that clinicians should have a high index of suspicion of HLA-B27 positivity, if a case of AML develops arthritis during chemotherapy, since early introduction of immunosuppressive medications for arthritis may reduce morbidity and prevent delay in the administration of further chemotherapy cycles.



Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Toivanen P. From reactive arthritis to rheumatoid arthritis. J Autoimmun 2001;16:369-71.
  • 2 Lee J, Kim H, Ahn JK, Hwang JW, Jang JH, Koh EM, et al. Ankylosing spondylitis in a patient with myelodysplastic syndrome: An association with HLA-B27 or coincidence? Rheumatol Int 2009;29:689-92.
  • 3 Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 2001;115:320-2.
  • 4 Lam SM, Ho HH, Dunn P, Luo SF. Association of ankylosing spondylitis with IgA-multiple myeloma: Report of a case and pathogenetic considerations. Taiwan Yi Xue Hui Za Zhi 1989;88:726-8.
  • 5 Raut SS, Talati SS, Parikh SK, Maniar VP, Gohel VL, Goyal DM. Reactive arthritis during induction phase therapy for acute myeloid leukaemia: Genetic predisposition due to HLA B27. Int J Med Appl Sci 2014;3:119-22.
  • 6 Gragert L, Fingerson S, Albrecht M, Maiers M, Kalaycio M, Hill BT. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood 2014;124:2657-65.
  • 7 Koch B, Kranzhöfer N, Pfreundschu M, Pees HW, Trümper L. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant 2000;26:673-5.
  • 8 Husby G, Tsuchiya N, Schwimmbeck PL, Keat A, Pahle JA, Oldstone MB, et al. Cross-reactive epitope with Klebsiella pneumoniae nitrogenase in articular tissue of HLA-B27+ patients with ankylosing spondylitis. Arthritis Rheum 1989;32:437-45.
  • 9 Mishra MN, Bharucha KM. HLA-B27 association with uveitis in an Asian Indian population. Iran J Immunol 2011;8:85-9.
  • 10 Leirisalo-Repo M. Therapeutic aspects of spondyloarthropathies - A review. Scand J Rheumatol 1998;27:323-8.